With new developments in CD20 x CD3 bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), community oncology providers are actively developing and adopting protocols to safely administer and manage the toxicities related to bispecific antibody therapies in the outpatient setting. This dynamic video activity features expert discussion on challenges and barriers to administration and adverse event management identified through real-world data obtained from a recent quality improvement initiative centered on bispecific antibody therapy for patients with R/R DLBCL in community oncology practices. You will also have access to download a newly developed "Adverse Event Management Playbook: Specifics for Bispecific Antibodies in Community Clinics" to help guide your clinic on adopting expert-informed protocols for adverse event management, care coordination, and patient education.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/navigating-adverse-event-management-bispecific-antibodies-relapsed-refractory
- Start Date: 2024-08-20 05:00:00
- End Date: 2024-08-20 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Genmab US, Inc. - Amount: 99750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all